Are you Dr. Sytkowski?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 36 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
Beth Israel Deaconess
One Deaconess Road
Boston, MA 02215Phone+1 617-632-9980- Is this information wrong?
Summary
- Dr. Arthur Sytkowski, MD is a pathologist in Boston, Massachusetts. He is currently licensed to practice medicine in Massachusetts. He is affiliated with Beth Israel Deaconess Medical Center and is an Associate Professor of Medicine at Beth Israel Deaconess Medical Center.
Education & Training
Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1977 - 1979- Brigham and Women's HospitalResidency, Internal Medicine, 1969 - 1971
Medical College of WisconsinClass of 1969
Certifications & Licensure
MA State Medical License 1973 - 2025
Awards, Honors, & Recognition
- Elected Member The American Society for Clinical Investigation, 1986
Clinical Trials
- A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD) Start of enrollment: 2017 Dec 18
- rVWF IN PROPHYLAXIS Start of enrollment: 2017 Nov 16
- Randomized Phase 2, Dose-finding Efficacy, Safety Study of ANF-RHO™ Versus Neulasta® in Chemotherapy-Induced Neutropenia Start of enrollment: 2017 Aug 03
Publications & Presentations
PubMed
- Phase 3 Study of Recombinant von Willebrand Factor in Patients With Severe von Willebrand Disease Who Are Undergoing Elective Surgery.Peyvandi, F.,Mamaev, A.,Wang, J. D.,Stasyshyn, O.,Timofeeva, M.,Curry, N.,Cid, A. R.,Yee, T. T.,Kavakli, K.,Castaman, G.,Sytkowski, A.> ;J. Thromb. Haemost.. 2018 Oct 27
- 67 citationsErythropoietin and cancer: the unintended consequences of anemia correction.Nataša Debeljak, Peter Solár, Arthur J. Sytkowski> ;Frontiers in Immunology. 2014 Nov 11
- 18 citationsHuman selenium binding protein-1 (hSP56) is a negative regulator of HIF-1α and suppresses the malignant characteristics of prostate cancer cells.Jee-Yeong Jeong, Jin-Rong Zhou, Chong Gao, Laurie Feldman, Arthur J. Sytkowski> ;BMB Reports. 2014 Jul 1
- Join now to see all
Grant Support
- Protein Dimers As Cancer TherapeuticsNational Cancer Institute2001–2004
- Chemopreventive Action Of Human Selenium Binding ProteinNational Cancer Institute2002
- New System For The Study Of ErythropoiesisNational Institute Of Diabetes And Digestive And Kidney Diseases1994–1996
- A New System For The Study Of ErythropoiesisNational Institute Of Diabetes And Digestive And Kidney Diseases1987–1993
- New System For The Study Of ErythropoiesisNational Institute Of Diabetes And Digestive And Kidney Diseases1992
- A New System For The Study Of ErthyropoiesisNational Institute Of Diabetes And Digestive And Kidney Diseases1986
- A New Cell System For The Study Of ErythropoiesisNational Institute Of Diabetes And Digestive And Kidney Diseases1986
- A New System For The Study Of ErythropoiesisNat Inst Of Arthritis, Diabetes, Digestive &Kidney Diseases1985
- A New Cell System For The Study Of ErythropoiesisNat Inst Of Arthritis, Diabetes, Digestive &Kidney Diseases1985
Professional Memberships
- Member
- Member
Hospital Affiliations
Beth Israel Deaconess Medical CenterBoston, Massachusetts
